Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Discontinues Marketing of Photodynamic Diagnostic Agent "ALAGLIO® Divided Granules 1.5g"

05/09/2021 | 10:34pm EDT

Chugai Pharmaceutical Co., Ltd.

SBI Pharmaceuticals Co., Ltd.

Chugai Discontinues Marketing of Photodynamic Diagnostic Agent

"ALAGLIO® Divided Granules 1.5g"

TOKYO, May 10, 2021 --Chugai Pharmaceutical Co., Ltd.(Head office: Tokyo; President & CEO: Osamu

Okuda; "Chugai") and SBI Pharmaceuticals Co., Ltd.(Head office: Tokyo; Representative Director & President: Yoshitaka Kitao; "SBI Pharma") announced that the companies decided to terminate the license agreement for the photodynamic diagnostic agent "ALAGLIO® Divided Granules 1.5g ("ALAGLIO")" and that Chugai will consequently discontinue marketing of the product.

Both companies entered into a license agreement for ALAGLIO on March 13, 2017 which granted Chugai exclusive marketing rights of ALAGLIO in Japan. SBI Pharma obtained regulatory approval for ALAGLIO on September 27, 2017 for the indication of diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection, and Chugai launched the product on December 19 after the product had been listed on the National Health Insurance reimbursement price list on November 22.

Chugai will discontinue marketing and information provision for ALAGLIO on May 31, 2021. SBI Pharma will announce how these activities will be conducted from June 1, 2021.

Chugai and SBI Pharma will corporate to accomplish a smooth transition and maintain promotion of proper use of the product during the transition period.

Trademarks used or mentioned in this release are protected by law.

Contact Information

Corporate Communications Dept.,

SBI Pharmaceuticals Co., Ltd

Chugai Pharmaceutical Co., Ltd.

Contact from the press

Marketing & Sales Dept.

Media Relations Group

Mailinfo_ala@sbigroup.co.jp

TEL: +81-3-3273-0881

Mail: pr@chugai-pharm.co.jp

Contact from analysts/investors

Investor Relations Group

TEL: +81-3-3273-0554

Mail: ir@chugai-pharm.co.jp

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 10 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2021 02:33:05 UTC.


© Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD.
04:42aTOSHIBA  : board chair likely to scrape through with reappointment at crucial AG..
RE
04:05aCHUGAI PHARMACEUTICAL  : Obtains Regulatory Approval for FoundationOne CDx Cance..
PU
06/21TOSHIBA  : releases internal report ahead of shareholder vote
RE
06/21TOSHIBA  : releases internal report ahead of shareholder vote
RE
06/18TOSHIBA  : Former U.S. Ambassador throws support behind embattled Toshiba board ..
RE
06/18Former u.s. ambassador to japan john roos issues statement on toshiba corp bo..
RE
06/18Ahead of pivotal AGM, Toshiba board chairman vows to be 'agent of positive ch..
RE
06/17Toshiba's top shareholder calls board 'ineffective' - statement
RE
06/17Toshiba's top shareholder calls board 'ineffective' - statement
RE
06/16TOSHIBA  : chairman says he may leave once problems fixed - WSJ
RE
More news
Financials
Sales 2021 829 B 7 490 M 7 490 M
Net income 2021 244 B 2 207 M 2 207 M
Net cash 2021 451 B 4 077 M 4 077 M
P/E ratio 2021 29,5x
Yield 2021 1,40%
Capitalization 7 184 B 64 846 M 64 916 M
EV / Sales 2021 8,12x
EV / Sales 2022 8,02x
Nbr of Employees 7 555
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 4 370,00 JPY
Average target price 4 777,69 JPY
Spread / Average Target 9,33%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-22.77%61 483
JOHNSON & JOHNSON4.10%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.09%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.07%202 639